Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19

por Birabaharan, Morgan, Martin, Thomas C.S.
Publicado 2022

Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination

por Martin, Thomas C. S., Vinetz, Joseph M.
Publicado 2018

Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Mode...

por Martin, Natasha K., Thornton, Alicia, Hickman, Matthew, Sabin, Caroline, Nelson, Mark, Cooke, Graham S., Martin, Thomas C. S., Delpech, Valerie, Ruf, Murad, Price, Huw, Azad, Yusef, Thomson, Emma C., Vickerman, Peter
Publicado 2016

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation

por Martin, Natasha K., Vickerman, Peter, Dore, Gregory J., Grebely, Jason, Miners, Alec, Cairns, John, Foster, Graham R., Hutchinson, Sharon J., Goldberg, David J., Martin, Thomas C.S., Ramsay, Mary, Hickman, Matthew
Publicado 2016

Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000–2015

por Chaillon, Antoine, Sun, Xiaoying, Cachay, Edward R, Looney, David, Wyles, David, Garfein, Richard S, Martin, Thomas C S, Jain, Sonia, Mehta, Sanjay R, Smith, Davey M, Little, Susan J, Martin, Natasha K
Publicado 2019

Risk of COVID-19 after natural infection or vaccination

por Rick, Anne-Marie, Laurens, Matthew B., Huang, Ying, Yu, Chenchen, Martin, Thomas C.S., Rodriguez, Carina A., Rostad, Christina A., Maboa, Rebone M., Baden, Lindsey R., El Sahly, Hana M., Grinsztejn, Beatriz, Gray, Glenda E., Gay, Cynthia L., Gilbert, Peter B., Janes, Holly E., Kublin, James G., Huang, Yunda, Leav, Brett, Hirsch, Ian, Struyf, Frank, Dunkle, Lisa M., Neuzil, Kathleen M., Corey, Lawrence, Goepfert, Paul A., Walsh, Stephen R., Follmann, Dean, Kotloff, Karen L.
Publicado 2023

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

por Branche, Angela R., Rouphael, Nadine G., Diemert, David J., Falsey, Ann R., Losada, Cecilia, Baden, Lindsey R., Frey, Sharon E., Whitaker, Jennifer A., Little, Susan J., Anderson, Evan J., Walter, Emmanuel B., Novak, Richard M., Rupp, Richard, Jackson, Lisa A., Babu, Tara M., Kottkamp, Angelica C., Luetkemeyer, Anne F., Immergluck, Lilly C., Presti, Rachel M., Bäcker, Martín, Winokur, Patricia L., Mahgoub, Siham M., Goepfert, Paul A., Fusco, Dahlene N., Malkin, Elissa, Bethony, Jeffrey M., Walsh, Edward E., Graciaa, Daniel S., Samaha, Hady, Sherman, Amy C., Walsh, Stephen R., Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana M., Martin, Thomas C. S., Kamidani, Satoshi, Smith, Michael J., Ladner, Benjamin G., Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert L., Mulligan, Mark J., Lyke, Kirsten E., Posavad, Christine M., Meagher, Megan A., Stephens, David S., Neuzil, Kathleen M., Abebe, Kuleni, Hill, Heather, Albert, Jim, Telu, Kalyani, Mu, Jinjian, Lewis, Teri C., Giebeig, Lisa A., Eaton, Amanda, Netzl, Antonia, Wilks, Samuel H., Türeli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Montefiori, David C., Makowski, Mat, Smith, Derek J., Nayak, Seema U., Roberts, Paul C., Beigel, John H.
Publicado 2023